What question did this study set out to answer?

This study assesses the impact of oral azacitidine maintenance on overall survival in patients with t-AML or AML-MR after CPX-351 treatment.

December 8, 2025BloodOpen Access

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study finds oral AZA maintenance improves overall survival in t-AML and AML-MR patients after CPX-351, suggesting benefits.

This study assesses the impact of oral azacitidine maintenance on overall survival in patients with t-AML or AML-MR after CPX-351 treatment.
Conducted a real-world, retrospective, multi-center study across 11 centers in 4 countries.
Included AML patients receiving oral AZA maintenance after CPX-351 from 2020 to 2024.
Analyzed patient characteristics, treatment patterns, and survival outcomes descriptively.
Total of 34 patients with AML-MR (82.4%) or t-AML (14.7%) included.
Median overall survival from oral AZA introduction was 28.2 months.
MRD status at oral AZA introduction was examined, showing differences in OS between MRD positive and negative patients.

Uy et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark